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Abstract
Background: G-protein-coupled receptors (GPCRs) are prime candidates for novel cancer prevention and treatment
strategies. We searched for differentially expressed GPCRs in node positive gastric carcinomas.
Methodology/Principal Findings: Differential expression of GPCRs in three node positive vs. three node negative intestinal
type gastric carcinomas was analyzed by gene array technology. The candidate genes CXCL12 and its receptor CXCR4 were
validated by real-time reverse-transcription polymerase chain reaction in an independent set of 37 gastric carcinomas.
Translation was studied by immunohistochemistry in 347 gastric carcinomas using tissue microarrays as well as in 61
matching lymph node metastases. Protein expression was correlated with clinicopathological patient characteristics and
survival. 52 GPCRs and GPCR-related genes were up- or down-regulated in node positive gastric cancer, including CXCL12.
Differential expression of CXCL12 was confirmed by RT-PCR and correlated with local tumour growth. CXCL12
immunopositivity was negatively associated with distant metastases and tumour grade. Only 17% of gastric carcinomas
showed CXCR4 immunopositive tumour cells, which was associated with higher local tumour extent. 29% of gastric
carcinomas showed CXCR4 positive tumour microvessels. Vascular CXCR4 expression was significantly associated with
higher local tumour extent as well as higher UICC-stages. When expressing both, CXCL12 in tumour cells and CXCR4 in
tumour microvessels, these tumours also were highly significantly associated with higher T- and UICC-stages. Three lymph
node metastases revealed vascular CXCR4 expression while tumour cells completely lacked CXCR4 in all cases. The
expression of CXCL12 and CXCR4 had no impact on patient survival.
Conclusions/Significance: Our results substantiate the significance of GPCRs on the biology of gastric carcinomas and
provide evidence that the CXCL12-CXCR4 pathway might be a novel promising antiangiogenic target for the treatment of
gastric carcinomas.
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Introduction
Gastric cancer is one of the most common cancers worldwide,
ranking fourth in overall frequency and accounting for over 650,000
deaths annually [1]. The mortality of gastric cancer is only excelled
by lung cancer. Early gastric cancer often causes no specific
symptoms. The lack of early symptoms delays the diagnosis.
Consequently, 80–90% of Western patients with gastric cancer
present with advanced tumours when local or distant metastases had
already occured [1]. The lymph node status, especially the ratio of
metastasis-positive/metastasis-negative lymph nodes, is the strongest
prognostic factor of gastric cancer [2]. The 5-year survival rate for
patients with 1–6 lymph node metastases is 44% and ending with
only 11% in patients with more than 15 positive lymph nodes.
Partial or total gastrectomy, combined with adjuvant radiotherapy
and/or chemotherapy as indicated, promises complete cure only in
patients with early stage disease. In metastatic disease, currently used
radiotherapeutic and chemotherapeutic regimens have poor efficacy
and treatment resistant disease progression leads to death within few
months [3]. To date, there exists no specific predictive marker like
HER2 in breast carcinoma, EGFR in non small cell lung carcinoma
or K-RAS in colorectal carcinoma, which enables a more
individualized therapeutic strategy. Therefore, new molecular-
targeted therapeutic approaches are needed.
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family of cell-surface molecules, which relay signals via GTP-binding
protein (G-protein) -initiated second messenger cascades into the cell
[4]. GPCRs are regulated by many agonists, but all share a
characteristic core composed of seven transmembrane a-helices,
which are linked through three intra- and three extracellular loops.
These receptors control key physiological functions, including
neurotransmission, hormone and enzyme release from endocrine
and exocrine glands, immune responses, muscle contraction and
blood pressure regulation to name a few [4].
Malignant cells often hijack the normal physiological functions
of GPCRs to survive, proliferate autonomously and evade the
immune system. Furthermore GPCRs play a central role in
tumour-induced angiogenesis and cancer metastasis. Many solid
tumours rely on GPCRs to elicit an angiogenic response either by
acting on endothelial or stromal components directly or through
regulation of the release or activity of other angiogenic mediators
such as vascular endothelial growth factor (VEGF) or basic
fibroblast growth factor (bFGF) by stromal and immune cells [5].
Cancer cells manipulate GPCRs to attract endothelial cells and
lead them to invade the tumour mass, thereby forming new vessels
to provide nutrient and oxygen. Many cancers metastasize to
specific organs, what frequently is caused by the aberrant
expression of GPCRs in cancer cells - especially chemokine
receptors - concomitant with the release of chemokines from the
secondary organs [6].
Drug delivery, tumour imaging and biomarkers predicting
malignancy are applications of GPCRs to highlight: Radio-
labelled peptides that bind to GPCRs might have broad
applications for cancer diagnosis and therapy [7]. Ligands that
bind GPCRs have also been conjugated to cytotoxic agents to
specifically target malignant cells that overexpress these receptors,
therefore reducing side effects [8]. Furthermore, GPCRs might be
valuable biomarkers for cancer diagnosis as proven by studies in
prostate cancer [9].
Therefore, we aimed to (i) assess differentially expressed GPCRs
in nodal negative versus nodal positive intestinal type gastric
carcinoma by GeneChip array technique. (ii) Transcription of
candidate genes was validated by real-time reverse-transcription
polymerase chain reaction (real-time RT-PCR). We evaluated the
translation and histoanatomical distribution of the chemokine
CXCL12 and its corresponding chemokine receptor CXCR4 in a
large series of 347 gastric carcinoma samples immunohistochem-
ically using the tissue microarray-technology as well as in 61
matching lymph node metastases on conventional slides (iii). We
correlated the translational expression patterns with an ample set
of clinicopathological patient characteristics, including patient
survival (iv).
Results
Differential gene expression in node negative and node
positive gastric cancer tissue
First, we studied the differential expression of mRNA in a series
of 6 intestinal type gastric cancer patients (3 with and 3 without
lymph node metastases) using the GeneChipH Human Genome
U133 Plus 2.0 Array from Affymetrix which detects 47,000
transcripts and variants as well as 38,500 well characterized
human genes. mRNA was extracted and transcribed only from
tissue samples obtained from the primary tumours. A total of 115
transcripts were found to be up- and 219 to be down-regulated in
node positive gastric cancer compared with node negative gastric
cancers (table S1). Next we searched for differentially expressed
GPCRs. We identified 52 GPCRs and GPCR-related genes,
which were up- or down-regulated with a fold change factor of
.1.5 (table S2).
In silico analysis
We then searched the ENTREZ data base of the ‘‘National Center
for Biotechnology Information (NCBI)’’ for entries of the GPCRs and
GPCR-ligands and their putative role in tumour biology. The
significance of the angiotensin II type 1-receptor in gastric cancer
was previously verified by our own group [10]. Several studies had
shown that the expression of the duffy blood group chemokine
receptor (DARC) correlated inversely with the prevalence and
prognosis of prostate cancer [11–13]. In the animal model of
breast cancer the expression of EDG2 correlated with the
incidence of lung metastases [14]. FPRs mediate the effect of
annexin 1 on cell motility and invasion, which are important for
the metastatic potential of tumour cells [15]. LGR5 was recently
shown to be a stem cell marker of cells of the small intestine and
colon and stem-cell specific loss of Apc results in progressively
growing neoplasias [16]. Collectively, these data provide evidence
that our approach identified GPCRs and GPCR-ligands that may
be involved in gastric cancer biology. Concerning chemokine
receptors and chemokines, the expression of the chemokines
CCL2 and CXCL12 were increased in nodal positive gastric
cancer compared to nodal negative cases (supplementary table S2).
Since the CXCL12-CXCR4 axis plays a prominent role in
tumourigenesis, promoting angiogenesis and migration of tumour
cells to metastatic sites [17–19], we selected CXCL12 and its
receptor CXCR4 for further analyses.
Transcription of CXCL12 and CXCR4 in gastric cancer
The differential expression of CXCL12- and CXCR4-mRNA
was validated by real-time RT-PCR in an independent set of 37
intestinal type gastric carcinoma samples. We compared non-
neoplastic mucosa with the primary tumour as well as primary
tumours of node negative with primary tumours of node positive
cancers.
CXCL12 expression was significantly increased in gastric
carcinoma compared with non-neoplastic mucosa (p=0.033).
Confirming the array data, CXCL12 expression was also up-
regulated in nodal positive gastric carcinoma compared with nodal
negative cases. However, this difference did not reach statistical
significance (p=0.132; figure 1a). Concerning local tumour
growth, there was no significant difference in CXCL12 expression
in pT1/T2 stage tumour versus pT3/T4 tumours. But interest-
ingly, CXCL12 expression showed a significant association in
pT1/pT2a versus pT2b/T3/T4 (p=0.049; figure 1b).
There was neither a difference of CXCR4 expression in gastric
carcinoma versus non-neoplastic tissue (p=0.229) nor in nodal
negative versus nodal positive gastric carcinoma (p=0.22;
figure 1c). Comparing CXCR4 expression with the local tumour
extent, CXCR4-mRNA levels increased with the local tumour
growth (p=0.079; figure 1d).
Translation of CXCL12 in gastric carcinoma, correlation
with clinicopathological parameters and survival analyses
The translation and histoanatomical distribution of CXCL12
was subsequently studied by immunohistochemistry in 347 gastric
carcinoma samples. In 291 cases, CXCL12 immunoreactivity was
assessable. Tumour cells expressed CXCL12 in 244 of 291 (84%)
samples. A strong cytoplasmic and membranous immunoreaction
was observed in 143 (49%) cases and a weak staining in 101 (35%).
47 tumours (16%) lacked CXCL12-immunoreactivity. All tumour
samples showed a distinct CXCL12 positivity of the vascular
CXCR4 in Gastric Cancer
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(figure 2a-c). The statistical analyses showed a significant
correlation between the expression of CXCL12 in tumour cells
and distant metastases (p=0.043) as well as tumour grade
(p=0.0064). All other clinicopathological parameters showed no
association with CXCL12 expression in tumour cells (table 1).
When dividing the cohort into two groups, i.e. intestinal type and
diffuse type gastric carcinoma, no correlation was found between
CXCL12 expression and any clinicopathological parameter of
either group (data not shown). The CXCL12 expression in tumour
cells had no impact on patient survival (entire group: p=0.830;
intestinal type carcinoma: p=0.766; diffuse type carcinoma:
p=0.817).
Translation of CXCR4 in gastric carcinoma, correlation
with clinicopathological parameters and survival analyses
Translation of CXCR4 was also studied by immunohistochem-
istry. Immunoreactivity in tumour cells was assessable in 293
tumour samples, of which only 6 (2%) showed an unequivocal
membranous staining (category 2+; figure 2d). Most of the
CXCR4 positive tumour specimens only revealed a faint
cytoplasmic CXCR4 immunoreactivity (category 1+, 44 cases,
15%; figure 2e). Nuclear CXCR4 immunoreactivity was not
observed in any case and any cell type. An overall of 83% (243 of
293) of the gastric carcinomas were immunonegative for CXCR4,
most of them showing concomitant CXCR4 positive leucocytes as
an internal positive control (figure 2f). Interestingly, as previously
observed in colorectal carcinomas, 86 of 293 gastric carcinomas
(29%) showed CXCR4 positive microvessels in the tumour stroma
with a strong CXCR4 immunoreactivity of endothelial cells
(figure 3a). The vascular nature of these delicate structures was
confirmed by a CD34 immunostaining (figure 3b).
When correlating CXCR4 expression in tumour cells with
various clinicopathological parameters, CXCR4 expression was
significantly associated with higher local tumour extent (T-status;
p=0.030). However, no further associations of tumoral CXCR4
expression and other clinicopathological variables were found
(table 2). When analyzing the subgroup of intestinal type gastric
carcinomas, no associations were found with any clinicopatholog-
ical parameter (data not shown).
Then we studied the correlation between CXCR4 expression
in endothelial cells (vascular CXCR4 expression, vCXCR4) of
tumour microvessels and various clinicopathological parame-
ters. Interestingly, the expression of CXCR4 in microvessels
correlated highly significantly with the local tumour growth (T-
category; p=0.0001) as well as with the UICC-tumour stage
(p=0.0059). Even in the subgroups of intestinal type and diffuse
type gastric carcinoma, vCXCR4 expression was significantly
associated with local tumour extent (intestinal type: p=0.004;
diffuse type: p=0.030) and UICC-tumour stage (intestinal type:
p=0.020). Furthermore vCXCR4 expression was significantly
associated with patient age (p=0.0148) in the entire group
(table 3).
Survival analysis showed that CXCR4 expression in tumour
cells of gastric carcinoma as well as in tumour microvessels had no
impact on survival.
Figure 1. Transcription of CXCL12 and CXCR4: Boxplots depicting overall distribution of CXCL12 in (a) nodal negative versus nodal positive
gastric carcinomas and in (b) pT1/T2a versus pT2b/T3/T4 gastric carcinomas. Overall distribution of CXCR4 in (c) nodal negative versus nodal positive
gastric carcinomas and (d) pT1/T2a versus pT2b/T3/T4 gastric carcinomas. Box boundaries: 25
th and 75
th percentiles; solid line: median; whiskers: 10
th
and 90
th percentiles.
doi:10.1371/journal.pone.0010087.g001
Figure 2. CXCL12 and CXCR4 expression in tumour cells: Gastric carcinoma samples revealing strong (a) and weak (b) CXCL12
immunoreactivity. Only few cases were CXCL12 negative (c). Note positive CXCL12 staining of blood vessels (arrow). Gastric carcinoma specimens
showing a clear cytoplasmic and membranous CXCR4 immunoreactivity were sparse (d). Few samples revealed a weak (e) CXCR4 staining whereas
most of the tumours lacked CXCR4 expression (f). Leukocytes served as internal positive control (arrows). Scale bar: a-f: 50 mm.
doi:10.1371/journal.pone.0010087.g002
CXCR4 in Gastric Cancer
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carcinoma
Since the CXCL12-CXCR4 axis has been shown to be involved
in tumour progression [17–19], we investigated the correlation of
the concomitant expression of CXCL12 and vCXCR4 with
clinicopathological parameters. Indeed, CXCL12-vCXCR4 pos-
itive tumours were associated with higher local tumour extent
(p=0.0014) and higher UICC stages (p=0.017). However, it had
no impact on patient survival, even in the subgroups of intestinal
and diffuse type gastric carcinoma.
Expression pattern of CXCL12 and CXCR4 in matching
lymph node metastases
The CXCL12-CXCR4 axis has been reported to be involved in
metastatic processes in various tumour entities. Therefore we
examined CXCL12 and CXCR4 immunoreactivity in a subset of
61 matching lymph node metastases. The CXCL12 expression
pattern was available for 46 metastases. Overall, 4 lymph node
metastases were CXCL12 negative like their corresponding
primary tumour. 40 lymph node metastases showed a clear
CXCL12 positivity according to the primary tumour. The staining
intensity was very heterogeneous showing strongly positive tumour
cells adjacent to faintly stained tumour cell clusters. However, two
metastases revealed CXCL12 immunoreactivity although no
CXCL12 expression has been detected in the primary tumour.
CXCR4 immunoreactivity was assessed in 54 lymph node
metastases. Interestingly, none of them showed any CXCR4
expression. Even those tumours (n=6), showing a faint CXCR4
positivity in the primary tumour, lacked CXCR4 expression in the
corresponding lymph node metastases. However, all lymph node
metastases revealed clearly CXCR4 positive lymphocytes, which
served as internal positive control. Interestingly, in three cases
intratumoural CXCR4 positive microvessels were detectable.
Discussion
G-protein-coupled receptors represent the largest family of
transmembrane receptors. Five percent of all human genes code
for more than 800 different GPCRs and approximately 80
different ligands were identified until now [20]. GPCRs are the
most common pharmacological targets in medicine, i.e. almost
30% of all drugs are directed against GPCRs. Evidence is
increasing that GPCRs may also be promising targets for cancer
therapy. In this study we aimed to find GPCRs that are
differentially expressed in node positive gastric cancers and hence
may be considered as future targets for gastric cancer treatment.
We found 52 GPCRs and GPCR-related genes that are up- or
down-regulated in node positive primary gastric cancer tissue
compared with node negative cancer. Several of the GPCRs were
formerly shown to be involved in tumour biology, such as AT1R,
EDG2, DARC, and FPR1 [10,11,14,15]. Most interestingly, our
list also included LGR5 [16], which was recently shown to be a
stem cell marker in the small intestine and colon. Furthermore,
specific loss of Apc in LGR5-positive cells results in progressively
growing neoplasias. Thus, in silico validation of our data supported
the hypothesis that GPCRs are involved in the tumour biology of
gastric cancer.
Our subsequent validation studies using a group of independent
patients showed that the GPCR-ligand CXCL12 is expressed in
tumour cells of the majority of gastric carcinomas. Furthermore,
CXCL12 expression is negatively associated with distant metas-
tases and tumour grade. To the contrary, only 17% of gastric
carcinomas showed CXCR4 immunopositive tumour cells, which
was associated with higher local tumour extent. Interestingly,
about one third of the gastric carcinomas showed CXCR4 positive
tumour microvessels. Vascular CXCR4 expression was signifi-
cantly associated with higher local tumour extent as well as higher
UICC-stages. When expressing both, CXCL12 in tumour cells
and CXCR4 in tumour microvessels, these tumours also were
significantly associated with higher T- and UICC-stages, support-
ing the role of the CXCL12-CXCR4 axis in neoangiogenesis of
gastric cancer.
Among the GPCRs, the chemokine system contributes
significantly to tumour progression through modulation of the
local inflammatory reaction, tumour cell proliferation, migration
and survival as well as neoangiogenesis [4]. The chemokine
receptor CXCR4 initially was found to regulate the homing of
lymphocytes in inflammation and represents a co-receptor for the
human immunodeficiency virus (HIV) [21]. Physiologically, the
CXCL12-CXCR4 axis is involved in migration of embryonic cells
of the central nervous system, bone marrow and heart [22,23]. It
plays a critical role in metastatic processes as shown for breast
Table 1. Correlation of CXCL12-expression in tumour cells
with clinicopathological patient characteristics.
Gastric carcinoma Patients CXCL12 immunoreactivity
01 P
Total 347
Age, years
#65, n (%) 138 20 (14) 118 (86) ns (p=0.525)
.65, n (%) 153 27 (18) 126 (82)
Gender
men, n (%) 187 32 (17) 155 (83) ns (p=0.621)
women, n (%) 103 15 (15) 88 (85)
T category
pT1/pT2a, n (%) 48 8 (17) 40 (83) ns (p=1.0)
pT2b/pT3/pT4, n (%) 241 39 (16) 202 (84)
pT1/pT2, n (%) 151 24 (16) 127 (84) ns (p=1.0)
pT3/pT4, n (%) 140 23 (16) 117 (84)
Lymph nodes
no metastases (%) 74 8 (11) 66 (89) ns (p=0.20)
Metastases (%) 215 39 (18) 176 (82)
pN0, n (%) 74 8 (11) 66 (89) ns (p=0.22)
pN1, n (%) 103 16 (16) 87 (84)
pN2, n (%) 78 14 (18) 64 (82)
pN3, n (%) 34 9 (26) 25 (74)
M category
pM0, n (%) 257 37 (14) 220 (86) p=0.043
pM1, n (%) 34 10 (29) 24 (71)
Grade
G1/G2, n (%) 77 5 (6) 72 (94) p=0.0064
G3/G4, n (%) 214 42 (20) 172 (80)
UICC
I, n (%) 57 10 (18) 47 (82) ns (p=0.262)
II, n (%) 73 7 (10) 66 (90)
III, n (%) 95 14 (15) 79 (85)
IV, n (%) 68 16 (24) 52 (76)
doi:10.1371/journal.pone.0010087.t001
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highly expressed in organs which are frequent sites of distant
metastases like lung, liver and lymph nodes [28]. In gastric
carcinoma, data concerning the CXCL12-CXCR4 pathway are
sparse [29]. There is some evidence that CXCR4 expressing
gastric carcinomas more likely develop a peritoneal spread of the
tumour, and malignant ascites contains high concentrations of
CXCL12 [30].
Comparing our gene array data with those obtained by RT-PCR
and immunohistochemistry, it was interesting to note that the
differential expression of CXCL12 in node positive gastric
carcinoma was confirmed on the transcriptional but not on the
translational level. Here, the immunohistochemical detection of
CXCL12 in tumour cells correlated only with distant metastases and
tumour grade but not with nodal spread. However, CXCL12 was
found not only in tumour cells, but also in endothelial and stromal
cells [31], and overall expression in the entire tissue compartment is
more difficult to assess by immunohistochemistry. To the contrary,
our transcriptional studies used tissue homogenates which integrate
all CXCL12 expressing cells of the tumour tissue. Nevertheless, it
has to be kept in mind that gene transcription does not always
correlate with mRNA translation and that the tumour biological
effect of CXCL12 may also depend on the presence and
histoanatomical distribution of CXCR4. In support of this
contention, we were able to show that concomitant expression of
CXCL12 in tumour cells and CXCR4 in tumour microvessels
correlated with local tumour growth and UICC-tumour stage.
It was reported that tumoural CXCR4 positivity significantly
correlates with the development of peritoneal carcinomatosis [30].
Furthermore, strong CXCR4 expression was significantly associ-
ated with lymph node metastases, higher UICC stages and a
reduced 5-year survival rate [32]. Our results appear to differ from
these previous studies. When evaluating CXCR4 immunoreactiv-
ity in tumour cells, a low expression rate was observed. Only 17%
of the tumour samples showed a mostly faint CXCR4 immuno-
reactivity. Furthermore, all 61 matching lymph node metastases
lacked CXCR4 expression. This staining pattern may explain,
why for example in intestinal type gastric carcinomas, CXCR4
expression only was significantly associated with the local tumour
growth (T-category) but not with other clinicopathological factors
as previously described. We used a thoroughly characterized
CXCR4 antibody with a higher specificity than commercially
available antibodies as shown by Fisher and colleagues [33]. This
difference in specificity could serve for different staining patterns.
For example, a nuclear CXCR4 expression, which was reported to
be associated with lymph node metastases in colorectal cancer, was
not seen in our series [34]. Furthermore, we never detected
CXCR4 positivity in stromal cells as described in a study of
Saigusa and colleagues [35]. To clarify, if the CXCR4-CXCL12
pathway ultimately contributes to generation of metastases in
gastric carcinoma, especially lymph node metastases, further
studies are needed.
About one third of the examined gastric carcinomas showed
CXCR4 positive tumour- surrounding microvessels. Tumour cells
require adequate supply of oxygen and nutrients to maintain
survival. Even with genetic abnormalities that dysregulate growth
and survival of individual cells, tumours cannot enlarge beyond 1–
2m m
3 without vascularisation and hypoxia-induced cell death
occurs. It has been shown that CXCR4 is expressed by endothelial
cells and stimulation of CXCR4 by CXCL12 has a proangiogenic
effect [36]. Furthermore, CXCR4 is a hypoxia inducible gene,
regulated by the hypoxia-induced factor 1a (HIF1a). When oxygen
is scarce like in rapidly growing tumours, HIF1a enhances the
expression CXCR4 [37]. The increased expression of CXCR4 in
endothelial cells observed in our tumour collective might be part of
an integrated hypoxic response of the growing tumour that allows
Figure 3. CXCR4 expression in tumour microvessels: Gastric carcinoma samples showing strong vascular CXCR4 immunoreactivity or lacking
CXCR4 expression (a,c), indicated by arrows. Vascular structures were confirmed by a CD34 immunostaining (b, d). Scale bar: a-d: 50 mm.
doi:10.1371/journal.pone.0010087.g003
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CXCR4 expression correlated significantly with the extent of local
tumour growth. In 8% of T1/pT2a tumours (4 of 52) and in 34% of
T2b/T3/pT4 tumours (81 of 239) CXCR4 positive microvessels
were detectable. T2b/T3/T4-stage gastric carcinomas more likely
harbour a hypoxic microenvironment than T1/T2a-stage tumours
and thereby might induce CXCR4 gene expression and angiogen-
esis. Detection of CXCR4 positive microvessels in large lymph node
metastases (.9 mm in diameter) corroborated these observations.
Furthermore, we have previously shown comparable results in
colorectal carcinoma [38]. Additionally, as shown in glioblastoma
multiforme [39], tumour samples revealing both, CXCL12 positive
tumour cells and CXCR4 positive microvessels were highly
significantly associated with high local tumour extent and high
UICC stages, further supporting the significance of a functional
CXCL12-CXCR4 axis in gastric cancer biology.
In summary, we show that GPCRs are differentially expressed
in gastric cancer tissue and may contribute to the tumour biology:
tumours expressing both, CXCL12 in tumour cells and CXCR4
in tumour surrounding microvessels, show a highly significant
association with local tumour growth and UICC stages. These
results, together with our previous data on colorectal carcinoma,
substantiate the role of the CXCL12-CXCR4 axis in tumour-
neoangiogenesis in gastrointestinal tumours. The CXCL12-
CXCR4 pathway might be novel promising antiangiogenic target
for the treatment of gastric carcinomas.
Materials and Methods
Tumour samples
Tissue samples of gastric cancer were obtained surgically at the
Charite ´ University Hospital Berlin (1995–2008). Fresh frozen
tissue of 6 cases of intestinal type gastric carcinoma was used for
GeneChip analysis (nodal negative: 3 patients; nodal positive: 3
patients; female-male-ratio: 1:2). An independent series of paired
cancerous and tumor-adjacent normal tissues from 37 intestinal
type gastric carcinomas were examined by real-time RT-PCR
Table 2. Correlation of CXCR4 expression in tumour cells with
clinicopathological patient characteristics.
Gastric carcinoma Patients
CXCR4 immunoreactivity
of tumour cells
01 P
Total 347
Age, years
#65, n (%) 142 119 (84) 23 (16) ns (p=0.757)
.65, n (%) 151 124 (82) 27 (18)
Gender
men, n (%) 187 154 (82) 33 (18) ns (p=0.629)
women, n (%) 105 89 (85) 16 (15)
T category
pT1/pT2a, n (%) 52 43 (83) 9 (17) ns (p=1.0)
pT2b/pT3/pT4, n (%) 239 199 (83) 40 (17)
pT1/pT2, n (%) 153 134 (88) 19 (12) p=0.030
pT3/pT4, n (%) 140 109 (78) 31 (22)
Lymph nodes
no metastases (%) 74 60 (86) 14 (14) ns (p=0.721)
Metastases (%) 217 181 (83) 36 (17)
pN0, n (%) 74 60 (86) 14 (14) ns (p=0.83)
pN1, n (%) 104 89 (86) 15 (14)
pN2, n (%) 79 64 (81) 15 (19)
pN3, n (%) 34 28 (82) 6 (18)
M category
pM0, n (%) 258 215 (83) 43 (17) ns (p=0.633)
pM1, n (%) 35 28 (80) 7 (20)
Grade
G1/G2, n (%) 78 69 (88) 9 (12) ns (p=0.163)
G3/G4, n (%) 215 174 (81) 41 (19)
UICC
I, n (%) 59 50 (85) 9 (15) ns (p=0.1413)
II, n (%) 73 66 (90) 7 (10)
III, n (%) 91 70 (77) 21 (23)
IV, n (%) 70 57 (81) 13 (19)
doi:10.1371/journal.pone.0010087.t002
Table 3. Correlation of vascular CXCR4 expression with
clinicopathological patient characteristics.
Gastric carcinoma Patients Vascular CXCR4 immunoreactivity
01 P
Total 347
Age, years
#65, n (%) 142 110 (77) 32 (23) p=0.0148
.65, n (%) 151 97 (64) 54 (36)
Gender
men, n (%) 187 132 (71) 55 (29) ns (p=1.0)
women, n (%) 105 74 (70) 31 (30)
T category
pT1/pT2a, n (%) 52 48 (92) 4 (8) p=0.0001
pT2b/pT3/pT4, n (%) 239 158 (66) 81 (34)
pT1/pT2, n (%) 154 124 (81) 30 (19) p=0.0001
pT3/pT4, n (%) 139 83 (60) 56 (40)
Lymph nodes
no metastases (%) 74 55 (74) 19 (26) ns (p=0.463)
Metastases (%) 217 151 (70) 66 (30)
pN0, n (%) 74 55 (74) 19 (26) ns (p=0.689)
pN1, n (%) 105 75 (71) 30 (29)
pN2, n (%) 79 52 (66) 27 (34)
pN3, n (%) 33 24 (73) 9 (27)
M category
pM0, n (%) 259 185 (71) 74 (29) ns (p=0.427)
pM1, n (%) 34 22 (65) 12 (35)
Grade
G1/G2, n (%) 78 54 (69) 24 (31) ns (p=0.773)
G3/G4, n (%) 215 153 (71) 62 (29)
UICC
I, n (%) 58 52 (90) 6 (10) p=0.0059
II, n (%) 74 51 (69) 23 (31)
III, n (%) 91 56 (62) 35 (38)
IV, n (%) 69 48 (70) 21 (30)
doi:10.1371/journal.pone.0010087.t003
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male-ratio: ,1:1, for detailed patient characteristics see table S3).
For immunohistochemical analyses, a patient cohort of 347
consecutive patients with gastric cancer was examined, comprising
194 intestinal type and 122 diffuse type carcinomas according to
the Laure ´n classification. 31 samples showed other histological
subtypes (i.e. mucinous, tubular, undifferentiated). Briefly, the
cohort consisted of 220 men and 127 women. The mean age of the
patients at the time of diagnosis was 64 years. Survival data was
available from 196 of these patients. Follow-up data for the other
patients was missing because these patients were not resident near
the hospital and were lost to follow-up. Out of 196 patients, 124
died during follow-up. Median follow-up for those patients still
alive at the endpoint of analysis was 33 months. Of 61 patients,
tissue of matching lymph node metastases was available (27
intestinal type, 26 diffuse type, 8 other histological subtypes). Only
patients with histologically confirmed gastric cancer and adequate
tissue available were included. Patients with neoadjuvantly treated
gastric carcinoma or other known malignancies were excluded
from the study. This project was approved by the local ethics
committee (ref. number EA1/06/2004).
GeneChip analysis
Total RNA was isolated with phenol-chloroform using the
mirVana
TM miRNA Isolation Kit (Ambion, Austin, USA).
Contaminating DNA was removed by DNase treatment (Turbo
DNAfree kit; Ambion, Austin, USA) at 37uC for 30 min. We used
the GeneChipH Human Genome U133 Plus 2.0 arrays (Affyme-
trix, Santa Clara, CA, USA) according to the manufacturers
protocol to analyze mRNA expression levels. Affymetrix Gene-
ChipH Operating Software (GCOS 1.4) automates the control of
GeneChipH Fluidics Stations and GeneChipH Scanner 3000.
Bioinformatics
Raw data were analyzed with the Affymetrix GeneChip
Operating Software (GCOS 1.4). The detection p-value of a
transcript determines the detection call, which indicates whether
the transcript is reliably detected (p,0.05; present) or not
detected (absent). To enable the comparison between chips the
data were scaled to a global intensity of 500. The Data Mining
Tool 3.0 (Affymetrix) and GeneSpring software package 7.2
(Silicon Genetics, Redwood City, CA) were used to average
results from different samples and perform statistical analysis to
compare between gastric cancer with (N1) and without (N0)
lymph node metastases. The data of six arrays were normalized
to account for variability in hybridization for probe pairs and
other hybridization artefacts. The normalization consists of the
following three steps: first, data transformation (set measurements
less than 300.0 to 300.0); second, per chip (normalize each chip to
the 50th percentile of the measurements taken from that chip);
and third, per gene (normalize each gene to the median of the
measurements for that gene). The fold change was calculated
for each gene as the arithmetic mean of the normalized
expression values of N1 divided by the arithmetic mean of the
normalized expression values of N0. Raw data from microarray
experiments were uploaded to the Gene Expression Omnibus
Database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
pzmjlcoscakugfc&acc=GSE17187).
Real-time reverse transcriptase polymerase chain
reaction
For cDNA synthesis, 2 mg of total RNA was reverse transcribed
using the Omniscript RT Kit (Qiagen). The gene-specific primers
were designed by the BioTeZ Berlin-Buch GmbH (Berlin,
Germany). Primer sequences were as follows: CXCR4 59 CAG
CAG GTA GCA AAG TGA CG, 39 CAG GGT TCC TTC
ATG GAG TC; CXCL12 59 CGA TTC TTC GAA AGC CAT
GT, 39CAC TTG TCT GTT GTT GTT CTT CAG; beta2-
microglobulin 59 ACC CCC ACT GAA AAA GAT GA, 39
ATC TTC AAA CCT CCA TGA TG. Real-time reverse-
transcriptase polymerase chain reaction (Real-time RT-PCR) was
carried out using the QuantiTect
TM SYBRH Green PCR Kit
(Qiagen) and the LightCycler System (Roche Diagnostics,
Mannheim, Germany). The comparative Ct values were normal-
ized to that of the housekeeping gene beta2-microglobulin. No
template controls (no cDNA in PCR) were run for each gene
to detect unspecific or genomic amplification and primer
dimerization.
Histology
For histological analyses, tissue samples were fixed in 10%
neutralized formalin and embedded in paraffin. Deparaffinized
sections were stained using hematoxylin and eosin. Gastric
carcinoma was classified according to the WHO classification
[1]. The pTNM stage was determined according to the UICC
guidelines.
Tissue microarray construction
Formalin-fixed and paraffin-embedded tissue samples were used
to generate tissue microarrays as described previously [40,41].
Briefly, three to six morphologically representative regions of the
paraffin ‘donor’ blocks were chosen. Tissue cylinders were
punched from these areas and precisely arrayed into a new
‘recipient’ paraffin block using a customer built instrument
(Beecher Instruments, Silver Spring, MD, USA). A minimum of
three tissue cylinders of 0.6 mm diameter were punched from each
sample. After completing the block construction, four micrometer
sections of the resulting tumour tissue microarray block were cut
for further analysis.
Immunohistochemistry
Immunostaining was carried out with an anti-CXCR4-antiserum
(dilution 1:100; rabbit polyclonal antiserum;[38]) and an anti-
CXCL12-antibody (dilution 1:100; mouse monoclonal IgG1; R&D
Systems, Minneapolis, MN, USA). Following antigen retrieval
(sodium-citrate, 465 min, 600 W, microwave oven), incubation with
the primary antibodies was performed in a moist chamber at 4uC
overnight. Slides were washed between steps with Tris-buffered saline.
Immunoreactions were visualized with the Super Sensitive Link Label
Detection System (BioGenex Laboratories, San Ramon, CA, USA)
combined with the SIGMAFAST
TM kit (Sigma-Aldrich, St. Louis,
MO, USA). The specimens were counterstained with hematoxylin.
Immunostaining with an anti-CD34-antibody (dilution 1:100; mouse
monoclonal IgG1, kappa; DAKO, Carpinteria, CA, USA) used the
Ventana Benchmark XT automated staining system (Ventana
Medical Systems, Tucson, AZ, USA). Omission of primary antibodies
served as negative controls. Normal human adrenal gland tissue
served as positive control for CXCR4, normal human tonsil tissue for
CXCL12. The CXCR4 immunoreactivity in tumour cells was
categorized as absent (0), faint cytoplasmic staining (1+), clear
cytoplasmic and/or clear membranous staining (2+). CXCR4
expression in tumour microvessels was recorded as positive or
negative. CXCL12 immunoreactivity in primary tumours was scored
as absent (0), weak cytoplasmic (1) or strong cytoplasmic (2). CXCL12
expression in lymph node metastases was scored as positive or
negative. All samples were evaluated by one pathologist (BI). When
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tissue loss during the transfer of the TMA sections onto the slides.
Statistical analyses
For statistical analyses 1+ and 2+ tumour samples were
considered as CXCR4 positive (1) whereas tumours with lack of
immunoreactivity were scored as negative (0). Vascular CXCR4
expression always showed a strong signal and was recorded as
positive (1) or negative (0). 1+ and 2+ CXCL12 immunoreactivity
was scored as positive, whereas tumour samples lacking CXCL12
immunoreactivity were scored as negative. Significance of
correlations between protein expression (CXCR4 and CXCL12)
and clinicopathological parameters was assessed by Fisher’s exact
test for 262 tables and by the chi squared test for larger tables.
Survival curves were fitted with the Kaplan-Meier method.
Differences in survival were assessed by the log rank test.
Real-time RT-PCR data was logarithmized to obtain approx-
imately normally distributed data. Results were evaluated with an
unpaired two-sided t-test. P-values,0.05 were considered as
statistically significant. Statistical analyses were performed using
the SPSS 17 statistical package (SPSS Inc., Chicago, IL, USA) or
the GraphPad Prism statistical software (GraphPad Software, Inc.
La Jolla, CA, USA).
Supporting Information
Table S1 Differentially expressed genes in the primary tumours
of node- negative (N0) vs. node-positive (N1) intestinal type
primary gastric carcinomas based on microarray analysis (fold
change factor .1.7).
Found at: doi:10.1371/journal.pone.0010087.s001 (0.32 MB
DOC)
Table S2 Differentially expressed GPCRs and GPCR-related
genes in the primary tumors of node-negative (N0) vs. node-
positive (N1) intestinal type primary gastric carcinomas based on
microarray analysis (fold change factor .1.5).
Found at: doi:10.1371/journal.pone.0010087.s002 (0.11 MB
DOC)
Table S3 Patient characteristics of RT-PCR validation sample
set.
Found at: doi:10.1371/journal.pone.0010087.s003 (0.06 MB
DOC)
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